MOLBIO vs PAR: Stock Comparison
MOLBIO DIAGNOSTICS is the larger company by market capitalisation. MOLBIO DIAGNOSTICS shows faster revenue growth, while PAR shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MOLBIO leads 3; PAR leads 3 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MOLBIO | PAR |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | MOLBIO | PAR |
|---|---|---|
| Live Price | ₹1,307.4 | ₹164.95 |
| Day Change | 0.03% | -1.96% |
| Volume | 26.98 L | 7.26 L |
| 52-Week High | ₹1,686.8 | ₹180 |
| 52-Week Low | ₹926.35 | ₹78.05 |
| Distance from 52W High | -22.49% | -8.36% |
Valuation
| Metric | MOLBIO | PAR |
|---|---|---|
| Market Cap | ₹15,042 Cr | ₹163 Cr |
| P/E Ratio | — | 8.55x |
| P/B Ratio | — | 0x |
| EPS | ₹4.91 | ₹3.83 |
| Book Value | — | ₹91.01 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | MOLBIO | PAR |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -12.2% |
| EPS Growth (TTM YoY) | 0% | -48.5% |
| Qtr Sales Growth | -2.2% | 59.51% |
| Qtr Profit Growth | 7.36% | 452.1% |
Profitability & Leverage
| Metric | MOLBIO | PAR |
|---|---|---|
| ROE | — | 11.71% |
| ROCE | — | 18.83% |
| Net Margin | 0% | 12.65% |
| Operating Margin | — | 16.81% |
| Debt to Equity | — | 0x |
Shareholding
As of Aug 2026 • change vs previous quarter| Metric | MOLBIO | PAR |
|---|---|---|
| Promoter Holding | 41.29% | 73.41% |
| FII Holding | 1.51% | 0% |
| DII Holding | 16.37% | 0.09%▲ 0.09 pp |
| Public Holding | 40.82% | 26.51%▼ 0.08 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MOLBIO DIAGNOSTICS and PAR.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.